Mordor Intelligence’s Post

MIT immunoengineer Michal “Mikki” Tal has been studying how a special protein that is sometimes found on the surface of the bacteria that cause Lyme disease can mimic a healthy cell and thus evade the body’s immune response. This could help explain why some patients don’t recover from Lyme and have to deal with chronic, debilitating symptoms. When long COVID came into the picture, Tal was struck by the similarities to chronic Lyme disease. So, she brought together a research team and began the MIT MAESTRO study with the aim of identifying novel biomarkers of chronic Lyme disease and long COVID and improving diagnostics and treatment outcomes. Learn more in this article from MIT Technology Review: https://lnkd.in/eyX2ckmP #projectlyme #lyme #tickbornediseases #lymediseaseawareness #chronicillness #chronicpain #health #tickbite #bacteria #medicine #chroniclyme #longcovid #science #research

📢 Join HELIOS and make a real difference. Participate in our surveys today! 🌍💉🔬 By participating in our surveys, you can help us gather essential data to drive innovation and harmonize haemoglobinopathy practices worldwide. Your insights are invaluable in creating a future where every patient receives the best possible care. Haemoglobinopathies, including conditions like sickle cell disease and thalassemia, affect millions of people worldwide. Accurate diagnosis, effective clinical practices, and robust data management are essential to improve outcomes for those living with these genetic disorders. HELIOS aims to map and harmonize current practices in haemoglobinopathies to ensure that every patient receives the best possible care. By participating in our surveys, you can contribute valuable insights that will help shape the future of haemoglobinopathy care globally. Be a part of HELIOS and contribute to a brighter future. ✨🌍💡 Join HELIOS: https://lnkd.in/d2BKhqwg #HELIOS #Healthcare #Haemoglobinopathies #MedicalResearch #JoinTheMission #SickleCellDisease #Thalassemia #GeneticDisorders #HealthcareTransformation #hemoglobinopathies #joinus 

Surprising yet true - nearly 25% of cancers are considered 'rare'. These uncommon cancers and tumors are often elusive, posing unique challenges to medical science. In the biopharma world, we are harnessing innovation and cutting-edge technology to provide solutions, one rare disease at a time. Join us in shedding light on these under-researched fields, bringing hope to those affected by these elusive diseases. #RareDiseases #CancerResearch #BiotechPharma #InnovativeHealthcare #FightingRareCancer

In November, we observe Crohn's & Colitis Awareness Month. Alimentiv is dedicated to advancing the well-being of those living with Crohn's disease and ulcerative colitis through our unwavering commitment to research. Alimentiv's Precision Medicine team is devoted to enhancing patient care by investing in translational research and cutting-edge technologies. We strive to pinpoint cell and tissue biomarkers that can be leveraged to customize therapies, ensuring the right patient receives the right drug at the right time. Understanding the unique effectiveness of drug therapies in different individuals is key. To bridge these gaps and elevate our approach to Crohn's disease and ulcerative colitis treatment, a comprehensive understanding of disease biology and drug mechanisms is essential. Learn More: https://bit.ly/3SwWeQK #CrohnsAndColitisAwarenessMonth #CrohnsAndColitis #Crohns #Colitis #IBD

🔍 #ICYMI: Check out this research investigating factors that could alter the likelihood of identifying a clinically actionable #germline #pathogenic variant in patients with #UC. 🧠 Learn More:

I am pleased to share a lite paper I authored with Dr. Madhuri Paul, NeoGenomics’ Client Engagement Manager. Diseases such as paroxysmal nocturnal hemoglobinuria (PNH) present a clinical challenge due to the difficulty of diagnosing and effectively treating patients. This publication, “Paroxysmal Nocturnal Hemoglobinuria: The Current Testing Landscape and Emerging Therapies” discusses improvements in the lives of those with rare diseases, including emerging therapies, and identifies opportunities through real-world data. #CancerTesting #Oncology #WhitePaper #LitePaper https://lnkd.in/gqQHWkA7

The link between EBV and Alzheimer's disease is not new, but not been investigated on the epitope level. Accordingly, this paper is quite interesting to further shed light on this hardly explored link. #ebv #alzheimer

🌍 Today, on #worldparkinsonsday, we raise awareness about Parkinson's disease and reaffirm our commitment to advancing research and care for those affected by this condition. Despite ongoing research efforts, the exact cause of Parkinson's disease remains elusive, highlighting the importance of collaborative initiatives like ours with Servier. Together, we aim to leverage #CausalAI and our #GeminiDigitalTwins to advance our understanding of Parkinson's Disease. Learn more about our collaboration with Servier ➡️ https://lnkd.in/epCxB6nU And read more about our work and poster presented at SfN, showcasing evidence from our Gemini Digital Twins that suggests that Alzheimer's disease and Parkinson's disease might share common genes and pathways that causally influence a neuro-common biomarker, along with disease-specific clinical progression rates ➡️ https://lnkd.in/eUtwbZYW #ShareYourSpark ⚡ #Aitia #ATeam #ParkinsonsDisease #ParkinsonsAwareness #CNS

Exciting research on Alzheimer's disease (AD) from Kyu-Young Sim's team! This study revealed significant antibody differences between AD patients and controls, particularly the down-regulation of an antibody targeting an Epstein-Barr virus (EBV) epitope. This finding links EBV reactivation to increased AD risk in females. Explore the full publication to see how our peptide microarrays contributed to these crucial insights: https://lnkd.in/dHNMMk6Q #AlzheimersResearch #PeptideMicroarrays #EpitopeMapping #ScientificResearch

#Alzheimer’s disease (AD) research has entered a new era with the recent positive phase 3 clinical trials of the anti-Aβ antibodies lecanemab and donanemab. ⁉ Why did it take 30 years 📅 to achieve these successes?   In a review, #Cell comes back to the lessons learnt from the previous trials, including: 💡 The finding that reducing fibrillar amyloid was key 💡 The need to select patients at relatively early stages of disease. 💡 #Biomarkers of the target pathologies, including amyloid and tau PET.   👉 Moving forward, the challenge will be to develop more efficacious therapies with greater efficiency. Novel trial designs, including combination therapies and umbrella and basket protocols, will accelerate clinical development. Better #diversity and inclusivity of trial participants are needed, and blood-based biomarkers may help to improve access for medically underserved groups.   #innovation #lifesciences   https://lnkd.in/e6td4jaJ